Shareholders of unichem laboratories have approved the reappointment of Pabitrakumar Bhattacharyya as Managing Director and Chief Executive Officer, alongside adopting the audited financial statements for FY26. The resolutions were passed at the company’s 63rd Annual General Meeting (AGM) held on August 11, 2026, with an overall voting participation rate of 81.2% among shareholders holding 7,04,05,750 shares.

The meeting was conducted via video conference in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars. Dr. Prakash A. Mody, Chairman, was absent due to personal reasons; Mr. Pranay Godha, Non-Executive Director, presided over the session. Statutory Auditors N.A. Shah Associates LLP and Secretarial Auditors Alwyn Jay & Co. were present to address queries.

Voting Participation Breakdown

The consolidated scrutinizer’s report, dated August 12, 2026, detailed the voting patterns across shareholder categories. Promoters and the Promoter Group held 4,94,40,586 shares and cast all their votes, representing 100% participation. Public Institutions held 85,20,924 shares, with a 90.25% voting turnout. Public Non-Institutions held 1,24,44,240 shares, recording a lower participation rate of 0.28%. E-voting was facilitated through National Securities Depository Limited (NSDL).

Key Resolutions Passed

All five resolutions placed before the members were passed with requisite majorities. The adoption of standalone and consolidated financial statements for FY26 received near-unanimous support, with only 11 and 12 votes cast against them respectively from public non-institutional shareholders.

Pabitrakumar Bhattacharyya (DIN: 07131152), who retires by rotation, was reappointed as a director via an ordinary resolution and subsequently as MD and CEO via a special resolution. Both resolutions saw strong support, though 440 votes were cast against his reappointment by public non-institutional shareholders. The remuneration for Cost Auditors Kishore Bhatia & Associates for the year ended March 31, 2027, was also ratified.

Governance and Compliance

Alwyn D'Souza of Alwyn Jay & Co. served as the scrutinizer for the e-voting process. The votes were unblocked on August 11, 2026, at 4:27 p.m., in the presence of two independent witnesses, Edion Dsouza and Krishnakant Adagale. The Company Secretary, Pradeep Gautam Bhandari, confirmed that the Statutory Auditors’ Report and Secretarial Auditor’s report contained no qualifications. The proxy register was not available for inspection as the facility is not applicable for meetings held entirely through video conference.

Unichem Laboratories reported a consolidated net profit of ₹41.47 crore for the quarter ended June 30, 2026, marking a significant turnaround from the net loss of ₹10.47 crore recorded in the corresponding quarter of FY25. The profitability shift was primarily driven by a 20.1% year-on-year increase in revenue from operations, which stood at ₹632.62 crore compared to ₹526.60 crore in Q1FY25. This revenue growth, coupled with effective cost management, resulted in an EBITDA margin expansion to 11% from 4.3% in the prior year period, signaling improved operational efficiency within the pharmaceutical segment.

The Board of Directors approved the unaudited consolidated and standalone financial statements during a meeting held on August 11, 2026. The results were reviewed by N. A. Shah Associates LLP, the statutory auditors, who issued an unmodified conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The standalone results also reflected this positive trend, with the company reporting a profit after tax of ₹5.53 crore, contrasting with a loss of ₹1.85 crore in the previous year's quarter.

Financial Performance Highlights

The following table summarises key consolidated financial metrics for the quarter alongside prior year comparatives and the full year ended March 2026:

Consolidated total income reached ₹648.23 crore, aided by other income rising to ₹15.61 crore from ₹6.82 crore in the prior year period. Total expenses increased moderately by 10.5% to ₹599.24 crore, indicating effective cost management despite higher operational volumes. Key expense components included cost of materials consumed at ₹190.02 crore and employee benefits expense at ₹103.31 crore.

Standalone Results and Subsidiary Contributions

On a standalone basis, Unichem Laboratories reported revenue from operations of ₹366.27 crore, a slight decline from ₹384.25 crore in Q1FY25. However, the entity turned profitable with a net profit of ₹5.53 crore, up from a loss of ₹1.85 crore. Standalone earnings per share stood at ₹0.79, compared to a loss of ₹0.26 per share in the previous year.

The auditor's report noted that subsidiaries Niche Generics Limited (UK) and Unichem Pharmaceuticals (USA), Inc. contributed significantly to the group's performance. These entities reported combined revenues of ₹470.28 crore and a net profit of ₹12.39 crore for the quarter. Other overseas subsidiaries, including entities in South Africa, Brazil, and China, contributed ₹23.59 crore in revenues. Additionally, during the quarter, the company invested USD 80,000 (equivalent to ₹0.76 crore) towards redeemable preference shares in its wholly owned subsidiary, Unichem (China) Pvt Ltd.

What the Numbers Show

The divergence between consolidated and standalone performance highlights the critical role of international operations in Unichem's profitability model. While the Indian parent entity saw flat revenue growth, the consolidated figures reflect strong international demand, particularly from its UK and US subsidiaries. The sharp expansion in EBITDA margin — from 4.3% to 11% — further underscores improved operating leverage across the group.

Notably, there were no exceptional items impacting the current quarter's bottom line, contrasting with the prior year's accounting adjustments related to European Commission fines and labor code provisions. Management continues to monitor developments pertaining to the New Labour Codes, which had resulted in a one-time provision of ₹15.40 crore in the previous fiscal year. The company also settled a European Commission fine demand of Euro 19.55 million in October 2025, with the interest component recognised as an exceptional item in FY26. No current tax charge was levied for the period due to the set-off of unabsorbed tax depreciation and business losses.